JNJ Johnson & Johnson

173.36
-1.03  -1%
Previous Close 174.39
Open 174.2
52 Week Low 133.65
52 Week High 174.5
Market Cap $456,367,095,469
Shares 2,632,482,092
Float 2,630,875,523
Enterprise Value $461,490,416,242
Volume 4,792,634
Av. Daily Volume 6,438,961
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
JNJ-78436735 (Ad26.COV2-S) - (ENSEMBLE-2)
COVID-19 vaccine - two-dose regimen
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
DARZALEX (Daratumumab) in combination with Pomalyst (pomalidomide) and dexamethasone
Multiple myeloma
Approved
Approved
FDA approval announced July 12, 2021.
DARZALEX (Daratumumab)
Newly Diagnosed Multiple Myeloma (NDMM)
Approved
Approved
FDA Approval announced June 28, 2019.
BALVERSA (erdafitinib)
Urothelial cancer
Approved
Approved
FDA Approval announced April 12, 2019.
DARZALEX (Daratumumab) + bortezomib, thalidomide and dexamethasone (VTd)
Multiple myeloma - candidates for autologous stem cell transplant (ASCT)
Approved
Approved
FDA Approval announced September 26, 2019.
SPRAVATO (esketamine)
Major depressive disorder (MDD)
Approved
Approved
FDA approval announced August 3, 2020.
SPRAVATO (esketamine)
Treatment resistant depression
Approved
Approved
FDA approval announced March 5, 2019.
ERLEADA (apalutamide)
Metastatic castration-sensitive prostate cancer (mCSPC).
Approved
Approved
FDA Approval announced September 18, 2019.
ERLEADA (apalutamide)
Non-metastatic castration-resistant prostate cancer (CRPC)
Approved
Approved
Approval announced February 14, 2018.
INVOKANA (canagliflozin)
Diabetic Kidney Disease
Approved
Approved
FDA Approval announced September 30, 2019.
INVOKANA (canagliflozin)
Type 2 diabetes
Approved
Approved
FDA Approval announced October 30, 2018.
Generic COPAXONE
Multiple sclerosis
Approved
Approved
Filed 2007. Approved April 16 2015.
DARZALEX (Daratumumab) and KYPROLIS (carfilzomib)
Multiple Myeloma
Approved
Approved
FDA approval announced August 20, 2020.
DARZALEX (Daratumumab)
Frontline multiple myeloma (non-transplant)
Approved
Approved
Approval announced May 7, 2018.
TREMFYA (Guselkumab) - (GALAXI 1)
Crohn's disease
Phase 2/3
Phase 2/3
Phase 2/3 trial initiation announced July 11, 2018.
TREMFYA (Guselkumab)
Plaque psoriasis
Approved
Approved
Approval announced February 27, 2019.
TREMFYA (Guselkumab)
Ulcerative colitis
Phase 2
Phase 2
Phase 2a initiation announced January 17, 2019.
TREMFYA (Guselkumab)
Psoriatic Arthritis
Approved
Approved
FDA Approval announced July 14, 2020.
TREMFYA (Guselkumab)
Plaque psoriasis
Approved
Approved
Approval announced July 13, 2017.
IMBRUVICA (Ibrutinib)
Second-line Chronic graft-versus-host disease (GVHD)
Approved
Approved
Approval announced August 2, 2017.
IMBRUVICA (Ibrutinib)
Marginal zone lymphoma
Approved
Approved
Approved January 19, 2017.
IMBRUVICA (ibrutinib) and RITUXAN (rituximab)
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Approved
Approved
FDA Approval announced April 21, 2020.
Nipocalimab (M281)
generalized myasthenia gravis (gMG)
Phase 2
Phase 2
Phase 2 trial met primary endpoint - June 15, 2020. Phase 3 trial to be initiated 1Q 2021.
JNJ-78436735 (Ad26.COV2-S) - (ENSEMBLE)
COVID-19 vaccine (single dose)
Approved
Approved
Phase 3 data released January 29, 2021. Efficacy rate 66% in overall population, 72% effective in U.S. and 57% in South Africa. EUA Approval by FDA announced February 27, 2021.
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Approved
Approved
FDA approval announced January 15, 2021.
Amivantamab
Non-small cell lung cancer (NSCLC)
BLA Filing
BLA Filing
BLA filing announced December 3, 2020.
Paliperidone
Schizophrenia
sNDA Filing
sNDA Filing
sNDA filing announced November 2, 2020.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
Approved
Approved
FDA Approval announced May 1, 2020.
Ponesimod
Relapsing multiple sclerosis
NDA Filing
NDA Filing
NDA filing announced March 18, 2020.
STELARA (USTEKINUMAB)
Ulcerative colitis
Approved
Approved
FDA Approval announced October 21, 2019.
XARELTO (rivaroxaban)
Reduce the Risk of Recurrent Venous Thromboembolism (VTE)
Approved
Approved
FDA approval announced October 14, 2019.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
Approved
Approved
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Approved
Approved
FDA approval announced August 27, 2018.
D/C/F/TAF
HIV
Approved
Approved
FDA Approval announced July 17, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Atabecestat
Alzheimer’s disease
Phase 2
Phase 2
Announced May 18, 2018 that dosing will be stopped.
ZYTIGA (abiraterone acetate) - LATITUDE
metastatic hormone-naïve prostate cancer (mHNPC)
Approved
Approved
sNDA approval announced February 8, 2018.
SIMPONI ARIA
Psoriatic arthritis (PsA)
Approved
Approved
Approval announced October 20, 2017.
STELARA (USTEKINUMAB)
Plaque psoriasis
Approved
Approved
Approval announced October 13, 2017.
SIMPONI ARIA
Ankylosing Spondylitis
Approved
Approved
Approval announced October 20, 2017.
Sirukumab
Rheumatoid arthritis
CRL
CRL
CRL issued September 22, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy.
XARELTO (rivaroxaban)
Coronary Artery Disease or Peripheral Artery Disease
Phase 3
Phase 3
Phase 3 trial stopped early due to positive efficacy - February 8, 2017.
Talacotuzumab
Acute myeloid leukemia (AML)
Phase 3
Phase 3
Phase 3 discontinuation announced October 17, 2017.

Latest News

  1. Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain management, today announced the appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board of Directors.

    "I am pleased that we are adding two such highly knowledgeable professionals to our Board of Directors. Each of them has valuable experience and we look forward to their contributions," commented Virpax Chairman and Chief Executive Officer Anthony P. Mack.

    About Gerald W. Bruce

    Gerald W. Bruce, the Company's Executive Vice President, and Commercial Operations Officer since August 2017, has spent over 30 years, including 20 years in senior leadership roles, in the pharmaceutical…

    Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain management, today announced the appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board of Directors.

    "I am pleased that we are adding two such highly knowledgeable professionals to our Board of Directors. Each of them has valuable experience and we look forward to their contributions," commented Virpax Chairman and Chief Executive Officer Anthony P. Mack.

    About Gerald W. Bruce

    Gerald W. Bruce, the Company's Executive Vice President, and Commercial Operations Officer since August 2017, has spent over 30 years, including 20 years in senior leadership roles, in the pharmaceutical and medical nutrition industries. Mr. Bruce was the Senior Vice President of Commercial Operations at NitroMed where he was responsible for building the commercial strategy and led the team responsible for the development and implementation of the commercial plan for the start-up company's first product for the treatment of heart failure. He spent close to ten years in the medical nutrition industry where he was Vice President of Sales for Nutricia North America, Danone Medical Nutrition Division.

    Mr. Bruce started his career at Johnson & Johnson (NYSE:JNJ) where he held leadership positions of increasing responsibility in sales and marketing ending with his role as Group Product Director of Analgesics. He then served as Vice President of Sales at Bristol-Myers Squibb Co. (NYSE:BMY) where he led the Cardiovascular and Metabolic sales force responsible for over $1.2 billion in sales. Following that, Mr. Bruce served as Vice President of Managed Markets where he led the team responsible for the development and implementation of the reimbursement strategy for Bristol-Myers Squibb's $7 billion US portfolio.

    Mr. Bruce received his bachelor's degree in Business Administration from Lincoln University and a master's degree in Leadership from the McDonough School of Business at Georgetown University. He currently serves as Chairman of the Board of Trustees for Lincoln University and serves on the executive committee of the Board at the National Sales Network.

    About Michael F. Dubin, CPA

    Mike Dubin is an accomplished senior executive, Certified Public Accountant, independent consultant, advisor, and thought leader with 40 years of experience and success in manufacturing, distribution, financial services, business and professional services, pharma, technology, retail and various other industries. His areas of expertise and experience also include leading executive teams, executive leadership training, operations management, profit optimization, board governance, financial reporting, and other financial management matters. Previously, Mr. Dubin held the title of Managing Partner, PA/SNJ Offices, with RSMUS LLP (RSM), a $2.8B professional services company with over 12,000 employees. He was presented with RSM's "National Achievement Award" in 2010, and was a finalist for the company's "National Integrity Award."

    Mr. Dubin obtained a BS in Economics (magna cum laude) from the Wharton School of Business, University of Pennsylvania. He served as a Board Member for RSM for four year and is also a board member and the Audit Committee Chairman for a privately held business in Philadelphia engaged in supplying energy efficiency services and facilities, and a board member and the Risk Management Committee Chairman for a commercial bank in Pennsylvania. Mr. Dubin is professionally affiliated with the PICPA and AICPA. He was also an adjunct faculty member and course teacher for the Wharton School of Business for two years and has also been a guest lecturer, at the Wharton School-University of Pennsylvania, Temple University, University of Scranton and Lehigh University. He also served as an expert witness/consultant for the Federal Deposit Insurance Corporation (FDIC) and the Resolution Trust Corporation (RTC).

    About Virpax Pharmaceuticals

    Virpax is developing branded, non-addictive pain management product candidates using its proprietary technologies that optimize target drug delivery. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop its PES200 product candidate to manage post-traumatic stress disorder (PTSD) and its MMS019 product candidate to inhibit viral replication caused by influenza or SARS-CoV-2. For more information, please visit www.virpaxpharma.com.

    Forward-Looking Statement

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

    These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on the Company's operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    View Full Article Hide Full Article
  2. WASHINGTON, July 29, 2021 /PRNewswire/ -- More than 30,000 women cancer victims would retain their constitutional right to have juries decide if talc in Johnson & Johnson's (NYSE:JNJ) baby products caused their ovarian cancer under bankruptcy reforms proposed Wednesday by key lawmakers in the U.S. Senate and House of Representatives.

    The Nondebtor Release Prohibition Act of 2021 would close controversial bankruptcy loopholes, including non-consensual third-party releases and the so-called "Texas Two-Step." Recent media reports indicate that Johnson & Johnson – with a market cap of more than $400 billion – is contemplating bankruptcy to avoid paying claims and damages that would likely cost a fraction of that amount. In a quarterly earnings report…

    WASHINGTON, July 29, 2021 /PRNewswire/ -- More than 30,000 women cancer victims would retain their constitutional right to have juries decide if talc in Johnson & Johnson's (NYSE:JNJ) baby products caused their ovarian cancer under bankruptcy reforms proposed Wednesday by key lawmakers in the U.S. Senate and House of Representatives.

    The Nondebtor Release Prohibition Act of 2021 would close controversial bankruptcy loopholes, including non-consensual third-party releases and the so-called "Texas Two-Step." Recent media reports indicate that Johnson & Johnson – with a market cap of more than $400 billion – is contemplating bankruptcy to avoid paying claims and damages that would likely cost a fraction of that amount. In a quarterly earnings report issued this week, J&J announced sales of $23.31 billion, a 27 percent increase year over year, and upgraded its annual sales forecast to $94.6 billion.

    "Many of us are shocked that Johnson & Johnson would consider abusing the bankruptcy process to avoid caring for the women and families they've harmed," says Deane Berg, whose 2013 trial resulted in the first jury verdict establishing a link between talcum powder and ovarian cancer. "Before we were harmed by J&J, we were loyal J&J customers. They've turned their back on all of us."

    Dozens of studies published in peer-reviewed journals during the past 25 years have shown a statistically significant association between talc use and ovarian cancer and mesothelioma. Documents produced at trial show that the company was aware of the dangers as far back as the 1960s.

    The bankruptcy reform proposal introduced by Sen. Elizabeth Warren (D-Mass.), Sen. Richard Durbin (D-Ill.) and Sen. Richard Blumenthal (D-Conn.) in the Senate, and Rep. Jerrold Nadler (D-N.Y.) and Rep. Carolyn Maloney (D-N.Y.) in the House, would address a growing trend in which a profitable company is able to quickly corral legal liabilities and debts into a separate corporate entity. Known as a "divisive merger" or the "Texas Two-Step," the liability-laden subsidiary is then reincorporated elsewhere and eventually declared bankrupt. The threat of bankruptcy is used to intimidate individuals who file lawsuits and to drive down the value of negotiated settlements.

    "These conscientious and well-informed lawmakers recognize that allowing highly profitable companies to shirk their responsibilities to society is reprehensible and can't be tolerated," says Andy Birchfield, Mass Tort Section Head at the Beasley Allen Law Firm, which represents thousands of women diagnosed with ovarian cancer after exposure to Johnson & Johnson Baby Powder and other talc-based products. "The courts – not the federal bankruptcy system – are the proper forum for resolving disputes between wrongdoers and the people they injure."

    The Nondebtor Release Prohibition Act would prohibit bankruptcy judges from allowing companies that are not a party to gain non-consensual releases of liability as part of the bankruptcy process. This tactic allows corporations to employ bankruptcy as a shield against liability. The legislation aligns with other proposed legislation – dubbed the SACKLER Act – introduced by Rep. Maloney.

    In addition, bankruptcy filings often result in indefinite delays that freeze ongoing lawsuits in state and federal courts. Sen. Warren's bill would limit stays for a duration of only 90 days.

    "These legislators should be applauded for recognizing the need to close the loopholes that allow powerful individuals and successful corporations to play blame-shifting with people's lives," says Michelle Parfitt, co-lead counsel in the federal talc MDL and a senior partner in the law firm Ashcraft & Gerel. "Whether it's a baby powder, a pharmaceutical or any other dangerous product, consumers need to be able to gain adequate compensation for any losses and injuries they've suffered. Without these proposals, that fundamental tenet of our justice system is at risk."

    About the Beasley Allen Law Firm

    Headquartered in Montgomery, Alabama, Beasley Allen is comprised of more than 70 attorneys and 200 support staff. One of the largest Plaintiffs law firms in the country, Beasley Allen is a national leader in civil litigation, with verdicts and settlements of more than $26 billion. For more information visit www.beasleyallen.com.

    About the Ashcraft & Gerel Law Firm

    Washington, D.C.-based Ashcraft & Gerel, LLP was first developed in 1953. The goal of the law firm is to help those who have been injured while on the job. Since its founding, this law firm has become one of the largest and most well-known personal injury firms in the U.S.

    Contact:

    Mark Annick



    800-559-4534

     

    Cision View original content:https://www.prnewswire.com/news-releases/women-cancer-victims-opposed-to-johnson--johnsons-texas-two-step-bankruptcy-ploy-urge-passage-of-reforms-introduced-by-warren-durbin-nadler-blumenthal-and-maloney-301344451.html

    SOURCE Beasley Allen Law Firm

    View Full Article Hide Full Article
  3. NEW BRUNSWICK, N.J., July 27, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) will participate in the Virtual Wells Fargo Healthcare Conference on Friday, September 10th.  Joaquin Duato, Vice Chairman of the Executive Committee will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time).

    This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

    A webcast replay will be available approximately 48-hours after the live webcast.

    (PRNewsfoto/Johnson & Johnson)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-to-participate-in-the-virtual-wells-fargo-healthcare-conference-301342552.html

    SOURCE Johnson & Johnson…

    NEW BRUNSWICK, N.J., July 27, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) will participate in the Virtual Wells Fargo Healthcare Conference on Friday, September 10th.  Joaquin Duato, Vice Chairman of the Executive Committee will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time).

    This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

    A webcast replay will be available approximately 48-hours after the live webcast.

    (PRNewsfoto/Johnson & Johnson)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-to-participate-in-the-virtual-wells-fargo-healthcare-conference-301342552.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
  4. NEW BRUNSWICK, N.J., July 21, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results for second-quarter. "Our second-quarter results showcase Johnson & Johnson's diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses," said Alex Gorsky, Chairman and Chief Executive Officer. "I'm so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These accomplishments exemplify our commitment to advancing transformational innovations that improve the health of people and communities…

    NEW BRUNSWICK, N.J., July 21, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results for second-quarter. "Our second-quarter results showcase Johnson & Johnson's diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses," said Alex Gorsky, Chairman and Chief Executive Officer. "I'm so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These accomplishments exemplify our commitment to advancing transformational innovations that improve the health of people and communities everywhere while continuing to deliver long-term value to all of our stakeholders."

    OVERALL FINANCIAL RESULTS



    Q2





    ($ in Millions, except EPS)

    2021

    2020

    %  Change

    Reported Sales

    $       23,312

    $       18,336

    27.1%

    Net Earnings

    6,278

    3,626

    73.1

    EPS (diluted)

    $           2.35

    $           1.36

    72.8%









    Q2





    Non-GAAP*($ in Millions, except EPS)

    2021

    2020

    %  Change

    Operational Sales1,2





    23.0%

    Adjusted Operational Sales1,3





    23.8

    Adjusted Net Earnings1,4

    6,625

    4,446

    49.0

    Adjusted EPS (diluted)1,4

    $           2.48

    $           1.67

    48.5%





    1

    Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 

    2

    Excludes the impact of translational currency

    3

    Excludes the net impact of acquisitions and divestitures and translational currency

    4

    Excludes intangible amortization expense and special items

     

    REGIONAL SALES RESULTS



    Q2



    %  Change

    ($ in Millions)

    2021

    2020

    Reported

    Operational1,2

    Currency

    Adjusted

    Operational1,3

    U.S.

    $      11,919

    $        9,539

    24.9%

    24.9

    -

    25.1

    International

    11,393

    8,797

    29.5

    20.9

    8.6

    22.4

    Worldwide

    $      23,312

    $      18,336

    27.1%

    23.0

    4.1

    23.8





    1

    Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

    2

    Excludes the impact of translational currency

    3

    Excludes the net impact of acquisitions and divestitures and translational currency



    Note: values may have been rounded

     

    SEGMENT SALES RESULTS



    Q2



    %  Change

    ($ in Millions)

    2021

    2020

    Reported

    Operational1,2

    Currency

    Adjusted

    Operational1,3

    Consumer Health

    $        3,735

    $        3,296

    13.3%

    9.2

    4.1

    10.0

    Pharmaceutical

    12,599

    10,752

    17.2

    13.6

    3.6

    14.1

    Medical Devices

    6,978

    4,288

    62.7

    57.2

    5.5

    58.7

    Worldwide

    $      23,312

    $      18,336

    27.1%

    23.0

    4.1

    23.8





    1

    Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

    2

    Excludes the impact of translational currency

    3

    Excludes the net impact of acquisitions and divestitures and translational currency



    Note: values may have been rounded

    Second Quarter 2021 SEGMENT COMMENTARY: 

    Consumer Health

    Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased 10.0%* inclusive of the market recovery from COVID-19 impacts, primarily in skin health/beauty.  Sales growth was driven by skin health/beauty products including NEUTROGENA, AVEENO, and OGX; over-the-counter products including ZYRTEC in upper respiratory products, international analgesics, and digestive health products; and BAND-AID® Brand Adhesive Bandages in wound care products. 

    Pharmaceutical

    Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 14.1%* driven by STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, and INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases.

    Medical Devices

    Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 58.7%*, primarily driven by the benefit of market recovery from COVID-19 impacts and the associated deferral of medical procedures in the prior year across all of our businesses including Surgery, Orthopaedics, Vision and Interventional Solutions.

    NOTABLE NEW ANNOUCEMENTS IN THE QUARTER:

    The information contained in this section should be read in conjunction with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the company's website at news releases.

    Regulatory

    Decisions

    TECNIS SYNERGY and TECNIS SYNERGY TORIC II IOLS a Next Generation Treatment for Cataract Patients Received Regulatory Approval and Launched in the U.S. and Canada

    (press release)

    (press release)

    RYBREVANT (amivantamab-vmjw) Receives U.S. FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

    (press release)

    PONVORY (ponesimod) receives European Commission approval for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features

    (press release)

    DARZALEX (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma

    (press release)

    DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) Receives U.S. FDA Approval for Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse1

    (press release)

    Regulatory

    Submissions

    Janssen granted Breakthrough Therapy Designation from the U.S. FDA for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma

    (press release)

    Janssen Submits Marketing Authorisation Application to the European Medicines Agency for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

    (press release)

    Janssen Submits New Drug Application to U.S. FDA for XARELTO (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

    (press release)

    Other

    Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa

    (press release)

    Janssen Discontinues Collaboration and License Agreement with argenx for Cusatuzumab

    (press release)

    ETHICON expands Advanced Bipolar Energy Portfolio with Launch of ENSEAL X1 Curved Jaw Tissue Sealer

    (press release)

    Johnson & Johnson Announces Positive New Data for the Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

    (press release)

    Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA and AVEENO Aerosol Sunscreen Products Due to the Presence of Benzene1

    (press release)

    1Subsequent to the quarter



    FULL-YEAR 2021 GUIDANCE:

    Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

    ($ in Billions, except EPS)

    April 2021 

    July 2021 (Base Business)

    July 2021 (incl. COVID Vx)

    Adjusted Operational Sales1,2

    Change vs. Prior Year

    8.7% - 9.9%

    9.5% - 10.5%

    12.5% - 13.5%

    Operational Sales2

    Change vs. Prior Year

    $89.3B - $90.3B

    8.2% – 9.4%

    $90.0B - $90.8B

    9.0% – 10.0%

    $92.5B - $93.3B

    12.0% – 13.0%

    Estimated Reported Sales3

    Change vs. Prior Year

    $90.6B - $91.6B

    9.7% – 10.9%

    $91.3B - $92.1B

    10.5% – 11.5%

    $93.8B - $94.6B

    13.5% – 14.5%









    Adjusted Operational EPS

    (Diluted)2,4

    Change vs. Prior Year

    $9.30 - $9.45

    15.8% - 17.7%



    $9.50 - $9.60

    18.4% - 19.6%

    Adjusted EPS (Diluted)3,4

    Change vs. Prior Year

    $9.42 - $9.57

    17.3% - 19.2%



    $9.60 - $9.70

    19.6% - 20.8%





    1

    Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

    2

    Non-GAAP financial measure; excludes the impact of translational currency

    3

    Calculated using Euro Average Rate: April 2021 = $1.19 and July 2021 = $1.19 (Illustrative purposes only)

    4

    Non-GAAP financial measure; excludes intangible amortization expense and special items



    Note: % may have been rounded

    Other modeling considerations will be provided on the webcast.

    WEBCAST INFORMATION:

    Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company's website at events-and-presentations

    ABOUT JOHNSON & JOHNSON:

    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

    NON-GAAP FINANCIAL MEASURES:

    *Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at quarterly-results.

    Copies of the financial schedules accompanying this earnings release are available on the company's website at quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investors section of the company's website at quarterly-results.

    NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," in the Company's most recently filed Quarterly Report on Form 10-Q and the Company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

     

    Johnson & Johnson and Subsidiaries

























    Supplementary Sales Data

































































    (Unaudited; Dollars in Millions)

    SECOND QUARTER



    SIX MONTHS











     Percent Change











    Percent Change



    2021



    2020



    Total



    Operations



    Currency



    2021



    2020



    Total



    Operations



    Currency

    Sales to customers by







































    segment of business















































































    Consumer Health







































        U.S.

    $   1,751



    1,557



    12.4

    %

    12.4



    -



    $   3,362



    3,297



    2.0

    %

    2.0



    -

        International

    1,984



    1,739



    14.1



    6.3



    7.8



    3,916



    3,624



    8.1



    3.3



    4.8



    3,735



    3,296



    13.3



    9.2



    4.1



    7,278



    6,921



    5.2



    2.7



    2.5









































    Pharmaceutical







































        U.S.

    6,869



    6,120



    12.2



    12.2



    -



    13,315



    12,181



    9.3



    9.3



    -

        International

    5,730



    4,632



    23.7



    15.4



    8.3



    11,483



    9,705



    18.3



    11.4



    6.9



    12,599



    10,752



    17.2



    13.6



    3.6



    24,798



    21,886



    13.3



    10.3



    3.0









































    Medical Devices







































        U.S.

    3,299



    1,862



    77.2



    77.2



    -



    6,353



    4,760



    33.5



    33.5



    -

        International

    3,679



    2,426



    51.6



    41.9



    9.7



    7,204



    5,460



    31.9



    24.5



    7.4



    6,978



    4,288



    62.7



    57.2



    5.5



    13,557



    10,220



    32.7



    28.7



    4.0









































    U.S.

    11,919



    9,539



    24.9



    24.9



    -



    23,030



    20,238



    13.8



    13.8



    -

    International

    11,393



    8,797



    29.5



    20.9



    8.6



    22,603



    18,789



    20.3



    13.7



    6.6

    Worldwide

    $ 23,312



    18,336



    27.1

    %

    23.0



    4.1



    $ 45,633



    39,027



    16.9

    %

    13.7



    3.2









































    Note:Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. 

     

    Johnson & Johnson and Subsidiaries







































    Supplementary Sales Data















































































    (Unaudited; Dollars in Millions)

    SECOND QUARTER



    SIX MONTHS











    Percent Change











    Percent Change



    2021



    2020



    Total



    Operations



    Currency



    2021



    2020



    Total



    Operations



    Currency

    Sales to customers by







































    geographic area















































































    U.S.

    $ 11,919



    9,539



    24.9

    %

    24.9



    -



    $ 23,030



    20,238



    13.8

    %

    13.8



    -









































    Europe

    5,668



    4,063



    39.5



    28.6



    10.9



    11,082



    8,890



    24.7



    15.6



    9.1

    Western Hemisphere excluding U.S.

    1,367



    1,133



    20.6



    12.7



    7.9



    2,791



    2,635



    5.9



    5.4



    0.5

    Asia-Pacific, Africa

    4,358



    3,601



    21.0



    14.8



    6.2



    8,730



    7,264



    20.2



    14.2



    6.0

    International

    11,393



    8,797



    29.5



    20.9



    8.6



    22,603



    18,789



    20.3



    13.7



    6.6









































    Worldwide

    $ 23,312



    18,336



    27.1

    %

    23.0



    4.1



    $ 45,633



    39,027



    16.9

    %

    13.7



    3.2









































    Note:Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

     

    Johnson & Johnson and Subsidiaries



















    Condensed Consolidated Statement of Earnings 







































    (Unaudited; in Millions Except Per Share Figures)

    SECOND QUARTER























    2021



    2020



    Percent







    Percent







    Percent



    Increase



    Amount



    to Sales



    Amount



    to Sales



    (Decrease)

    Sales to customers

    $ 23,312



    100.0



    $ 18,336



    100.0



    27.1

    Cost of products sold

    7,587



    32.5



    6,579



    35.9



    15.3

    Gross Profit

    15,725



    67.5



    11,757



    64.1



    33.8

    Selling, marketing and administrative expenses

    6,073



    26.1



    4,993



    27.2



    21.6

    Research and development expense

    3,394



    14.6



    2,707



    14.8



    25.4

    In-process research and development

    0



    0.0



    6



    0.0





    Interest (income) expense, net

    28



    0.1



    26



    0.2





    Other (income) expense, net

    (488)



    (2.1)



    24



    0.1





    Restructuring

    56



    0.2



    61



    0.3





    Earnings before provision for taxes on income

    6,662



    28.6



    3,940



    21.5



    69.1

    Provision for taxes on income

    384



    1.7



    314



    1.7



    22.3

    Net earnings

    $   6,278



    26.9



    $   3,626



    19.8



    73.1





















    Net earnings per share (Diluted)

    $     2.35







    $     1.36







    72.8





















    Average shares outstanding (Diluted)

    2,671.6







    2,665.5





























    Effective tax rate

    5.8

    %





    8.0

    %



























    Adjusted earnings before provision for taxes and net earnings (1)



















    Earnings before provision for taxes on income

    $   7,776



    33.4



    $   5,337



    29.1



    45.7

    Net earnings

    $   6,625



    28.4



    $   4,446



    24.2



    49.0

    Net earnings per share (Diluted)

    $     2.48







    $     1.67







    48.5

    Effective tax rate

    14.8

    %





    16.7

    %



























    (1)See Reconciliation of Non-GAAP Financial Measures.



















     

    Johnson & Johnson and Subsidiaries



















    Condensed Consolidated Statement of Earnings 







































    (Unaudited; in Millions Except Per Share Figures)

    SIX MONTHS























    2021



    2020



    Percent







    Percent







    Percent



    Increase



    Amount



    to Sales



    Amount



    to Sales



    (Decrease)

    Sales to customers

    $ 45,633



    100.0



    $ 39,027



    100.0



    16.9

    Cost of products sold

    14,650



    32.1



    13,641



    35.0



    7.4

    Gross Profit

    30,983



    67.9



    25,386



    65.0



    22.0

    Selling, marketing and administrative expenses

    11,505



    25.2



    10,196



    26.1



    12.8

    Research and development expense

    6,572



    14.4



    5,287



    13.5



    24.3

    In-process research and development

    0



    0.0



    6



    0.0





    Interest (income) expense, net

    76



    0.2



    (16)



    0.0





    Other (income) expense, net

    (1,370)



    (3.0)



    (655)



    (1.7)





    Restructuring

    109



    0.2



    119



    0.3





    Earnings before provision for taxes on income

    14,091



    30.9



    10,449



    26.8



    34.9

    Provision for taxes on income

    1,616



    3.6



    1,027



    2.7



    57.4

    Net earnings

    $ 12,475



    27.3



    $   9,422



    24.1



    32.4





















    Net earnings per share (Diluted)

    $     4.67







    $     3.53







    32.3





















    Average shares outstanding (Diluted)

    2,674.0







    2,671.0





























    Effective tax rate

    11.5

    %





    9.8

    %



























    Adjusted earnings before provision for taxes and net earnings (1)



















    Earnings before provision for taxes on income

    $ 16,067



    35.2



    $ 12,581



    32.2



    27.7

    Net earnings

    $ 13,549



    29.7



    $ 10,600



    27.2



    27.8

    Net earnings per share (Diluted)

    $     5.07







    $     3.97







    27.7

    Effective tax rate

    15.7

    %





    15.7

    %



























    (1)See Reconciliation of Non-GAAP Financial Measures.



















     

    Johnson & Johnson and Subsidiaries















    Reconciliation of Non-GAAP Financial Measures 





































    Second Quarter



    Six Months Ended



    (Dollars in Millions Except Per Share Data)

    2021



    2020



    2021



    2020



    Net Earnings, after tax- as reported

    $6,278



    $3,626



    $12,475



    $9,422





















    Pre-tax Adjustments 

















    Intangible Asset Amortization expense

    1,202



    1,127



    2,417



    2,245



    Litigation related

    (23)



    613



    (23)



    733



    IPR&D

    -



    6



    -



    6



    Restructuring related

    108



    115



    212



    233



    Acquisition, integration and divestiture related ¹

    14



    29



    (524)



    (933)



    Unrealized (gains)/losses on securities 

    (243)



    (533)



    (208)



    (206)



    Medical Device Regulation

    56



    37



    102



    51



    Other

    -



    3



    -



    3





















    Tax Adjustments

















    Tax impact on special item adjustments 2

    (135)



    (253)



    (248)



    (520)



    Tax legislation and other tax related

    (632)



    (324)



    (654)



    (434)



    Adjusted Net Earnings, after tax

    $6,625



    $4,446



    $13,549



    $10,600



    Average shares outstanding (Diluted)

    2,671.6



    2,665.5



    2,674.0



    2,671.0



    Adjusted net earnings per share (Diluted)

    $2.48



    $1.67



    $5.07



    $3.97



    Operational adjusted net earnings per share (Diluted)

    $2.42







    $4.91

























    Notes:















    1

    Acquisition, integration and divestiture related for the six months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.  The six months of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition. 



















    2

    The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.



     

    Johnson & Johnson and Subsidiaries













    Reconciliation of Non-GAAP Financial Measure































    Adjusted Operational Sales Growth

     SECOND QUARTER 2021 ACTUAL vs. 2020 ACTUAL 



     Segments 























    Consumer Health



     Pharmaceutical 



     Medical Devices 



     Total 



















     WW As Reported 



    13.3%



    17.2%



    62.7%



    27.1%

     U.S. 



    12.4%



    12.2%



    77.2%



    24.9%

     International 



    14.1%



    23.7%



    51.6%



    29.5%



















     WW Currency 



    4.1



    3.6



    5.5



    4.1

     U.S. 



    -



    -



    -



    -

     International 



    7.8



    8.3



    9.7



    8.6



















     WW Operational 



    9.2%



    13.6%



    57.2%



    23.0%

     U.S. 



    12.4%



    12.2%



    77.2%



    24.9%

     International 



    6.3%



    15.4%



    41.9%



    20.9%



















    General Surgery

















    Advanced Sterilization Products











    1.2



    0.2

     U.S. 











    0.0



    0.0

     International 











    1.9



    0.4



















    All Other Acquisitions and Divestitures



    0.8



    0.6



    0.3



    0.6

     U.S. 



    0.6



    (0.1)



    0.7



    0.1

     International 



    1.1



    1.5



    0.0



    1.0



















    WW Adjusted Operational



    10.0%



    14.1%



    58.7%



    23.8%

     U.S. 



    13.0%



    12.1%



    77.9%



    25.1%

     International 



    7.4%



    16.8%



    43.8%



    22.4%



















    Note: Percentages are based on actual, non-rounded figures and may not sum





     

    Johnson & Johnson and Subsidiaries













    Reconciliation of Non-GAAP Financial Measure































    Adjusted Operational Sales Growth

     SIX MONTHS 2021 ACTUAL vs. 2020 ACTUAL 



     Segments 























    Consumer Health



     Pharmaceutical 



     Medical Devices 



     Total 



















     WW As Reported 



    5.2%



    13.3%



    32.7%



    16.9%

     U.S. 



    2.0%



    9.3%



    33.5%



    13.8%

     International 



    8.1%



    18.3%



    31.9%



    20.3%



















     WW Currency 



    2.5



    3.0



    4.0



    3.2

     U.S. 



    -



    -



    -



    -

     International 



    4.8



    6.9



    7.4



    6.6



















     WW Operational 



    2.7%



    10.3%



    28.7%



    13.7%

     U.S. 



    2.0%



    9.3%



    33.5%



    13.8%

     International 



    3.3%



    11.4%



    24.5%



    13.7%



















    General Surgery

















    Advanced Sterilization Products











    0.8



    0.2

     U.S. 











    0.0



    0.0

     International 











    1.5



    0.4



















    All Other Acquisitions and Divestitures



    0.6



    0.5



    0.2



    0.4

     U.S. 



    0.5



    (0.1)



    0.5



    0.1

     International 



    0.7



    1.2



    0.0



    0.8



















    WW Adjusted Operational



    3.3%



    10.7%



    29.7%



    14.4%

     U.S. 



    2.5%



    9.2%



    33.9%



    13.9%

     International 



    4.0%



    12.6%



    26.0%



    14.8%



















    Note: Percentages are based on actual, non-rounded figures and may not sum





     







    REPORTED SALES vs. PRIOR PERIOD ($MM)











    REPORTED SALES vs. PRIOR PERIOD ($MM)





    SECOND QUARTER









    SIX MONTHS













    % Change















    % Change







    2021



    2020

    Reported

    Operational (1)

    Currency









    2021



    2020

    Reported

    Operational (1)

    Currency



    CONSUMER HEALTH SEGMENT (2) 





































    OTC





































    US



    $             675



    627

    7.7%

    7.7%

    -









    $          1,274



    1,316

    -3.2%

    -3.2%

    -



    Intl



    633



    522

    21.2%

    10.4%

    10.8%









    1,208



    1,181

    2.3%

    -4.7%

    7.0%



    WW



    1,307



    1,149

    13.8%

    8.9%

    4.9%









    2,482



    2,497

    -0.6%

    -3.9%

    3.3%



    SKIN HEALTH / BEAUTY





































    US



    659



    536

    23.0%

    23.0%

    -









    1,293



    1,195

    8.2%

    8.2%

    -



    Intl



    511



    471

    8.4%

    1.4%

    7.0%









    1,040



    929

    12.0%

    6.8%

    5.2%



    WW



    1,170



    1,007

    16.2%

    12.9%

    3.3%









    2,333



    2,124

    9.8%

    7.6%

    2.2%



    ORAL CARE





































    US



    165



    170

    -3.1%

    -3.1%

    -









    328



    346

    -5.2%

    -5.2%

    -



    Intl



    260



    227

    14.6%

    6.7%

    7.9%









    514



    446

    15.3%

    10.2%

    5.1%



    WW



    426



    397

    7.0%

    2.5%

    4.5%









    843



    792

    6.3%

    3.5%

    2.8%



    BABY CARE





































    US



    97



    96

    0.8%

    0.8%

    -









    193



    188

    2.4%

    2.4%

    -



    Intl



    290



    260

    11.5%

    6.6%

    4.9%









    583



    529

    10.2%

    9.0%

    1.2%



    WW



    387



    356

    8.6%

    5.0%

    3.6%









    776



    717

    8.1%

    7.3%

    0.8%



    WOMEN'S HEALTH





































    US



    3



    3

    -3.1%

    -3.1%

    -









    6



    7

    -16.0%

    -16.0%

    -



    Intl



    227



    199

    14.2%

    9.2%

    5.0%









    446



    427

    4.5%

    3.1%

    1.4%



    WW



    230



    202

    13.9%

    9.0%

    4.9%









    452



    434

    4.2%

    2.8%

    1.4%



    WOUND CARE / OTHER





































    US



    153



    126

    20.9%

    20.9%

    -









    268



    245

    9.3%

    9.3%

    -



    Intl



    64



    59

    7.3%

    -2.8%

    10.1%









    125



    111

    12.1%

    5.2%

    6.9%



    WW



    216



    185

    16.6%

    13.4%

    3.2%









    393



    356

    10.2%

    8.0%

    2.2%









































    TOTAL CONSUMER HEALTH





































    US



    1,751



    1,557

    12.4%

    12.4%

    -









    3,362



    3,297

    2.0%

    2.0%

    -



    Intl



    1,984



    1,739

    14.1%

    6.3%

    7.8%









    3,916



    3,624

    8.1%

    3.3%

    4.8%



    WW



    $          3,735



    3,296

    13.3%

    9.2%

    4.1%









    $          7,278



    6,921

    5.2%

    2.7%

    2.5%















































































    See footnotes at end of schedule





































     



    REPORTED SALES vs. PRIOR PERIOD ($MM)









    REPORTED SALES vs. PRIOR PERIOD ($MM)





    SECOND QUARTER







    SIX MONTHS













    % Change















    % Change



    PHARMACEUTICAL SEGMENT (2,3)



    2021



    2020

    Reported

    Operational (1)

    Currency









    2021



    2020

    Reported

    Operational (1)

    Currency









































    IMMUNOLOGY





































    US



    $          2,748



    2,362

    16.4%

    16.4%

    -









    $          5,161



    4,772

    8.2%

    8.2%

    -



    Intl



    1,483



    1,161

    27.7%

    18.2%

    9.5%









    2,984



    2,389

    24.9%

    17.0%

    7.9%



    WW



    4,231



    3,523

    20.1%

    17.0%

    3.1%









    8,145



    7,161

    13.7%

    11.1%

    2.6%



    REMICADE





































    US 



    540



    593

    -9.1%

    -9.1%

    -









    1,029



    1,218

    -15.6%

    -15.6%

    -



    US Exports (4)



    93



    133

    -30.0%

    -30.0%

    -









    150



    243

    -38.2%

    -38.2%

    -



    Intl



    255



    208

    22.4%

    11.1%

    11.3%









    487



    464

    4.9%

    -1.7%

    6.6%



    WW



    888



    935

    -5.1%

    -7.6%

    2.5%









    1,665



    1,925

    -13.5%

    -15.1%

    1.6%



    SIMPONI / SIMPONI ARIA





































    US



    290



    256

    12.8%

    12.8%

    -









    545



    528

    3.2%

    3.2%

    -



    Intl



    294



    289

    1.7%

    -3.8%

    5.5%









    601



    547

    9.8%

    4.5%

    5.3%



    WW



    584



    546

    6.9%

    4.0%

    2.9%









    1,146



    1,075

    6.6%

    3.8%

    2.8%



    STELARA





































    US



    1,496



    1,138

    31.4%

    31.4%

    -